The 5 most recent market catalysts affecting $YARW, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Yarrow Bioscience Launches Underwritten Public Offering To Fund Pipeline Development And Corporate Operations; No Terms Disclosed
Yarrow Bioscience is commencing an underwritten public offering to raise capital. This is a significant event for a clinical-stage biotechnology company as it provides the necessar…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 95
Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate
Yarrow Bioscience (YARW) announced Q2 earnings per share of $(2.14), which dramatically missed the analyst consensus estimate of $(0.22). This constitutes an 872.73% miss, indicati…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 65
BTIG Initiates Coverage On Yarrow Bioscience with Buy Rating, Announces Price Target of $58
BTIG analyst Julian Harrison initiated coverage on Yarrow Bioscience (YARW) with a 'Buy' rating and a $58 price target. This event is significant for YARW as new analyst coverage, …
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 65
TD Cowen Initiates Coverage On Yarrow Bioscience with Buy Rating
TD Cowen analyst Stacy Ku has initiated coverage on Yarrow Bioscience (YARW) with a 'Buy' rating. This event is significant because analyst coverage, especially from a reputable fi…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 85
Yarrow Bioscience And VYNE Therapeutics Compete Merger With Previously Announced Private Financings Totaling ~$200M; To Operate As Yarrow Bioscience And Trade On Nasdaq Capital Market From July 28 Under Ticker Symbol 'YARW'
This filing announces the completion of the merger between Yarrow Bioscience and VYNE Therapeutics, with the combined entity operating as Yarrow Bioscience and trading on Nasdaq un…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.